Dual anti-HER2 therapy combined with chemotherapy as a novel neoadjuvant treatment option for locally advanced HER2-positive and microsatellite stable colon cancer
Precision Clinical Medicine · 07.01.2025 · 8 (1)
DOI: 10.1093/pcmedi/pbae033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Precision Clinical Medicine, online erschienen am 10.12.2024. Verfasst von Huayang Pang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing 400030, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Institutions Performance Incentive Guidance Special Fund.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing 400030, China.
Förderung
- Research Institutions Performance Incentive Guidance Special Fund
Zitieren
APA
Pang, H., Chen, X., Yan, M., & Sun, H. (2025). Dual anti-HER2 therapy combined with chemotherapy as a novel neoadjuvant treatment option for locally advanced HER2-positive and microsatellite stable colon cancer. Precision Clinical Medicine, 8(1). https://doi.org/10.1093/pcmedi/pbae033
Vancouver
Pang H, Chen X, Yan M, Sun H. Dual anti-HER2 therapy combined with chemotherapy as a novel neoadjuvant treatment option for locally advanced HER2-positive and microsatellite stable colon cancer. Precision Clinical Medicine. 2025;8(1). doi:10.1093/pcmedi/pbae033
BibTeX
@article{Pang2025,
author = {Pang, Huayang and Chen, Xiufeng and Yan, Menghua and Sun, Hao},
title = {Dual anti-HER2 therapy combined with chemotherapy as a novel neoadjuvant treatment option for locally advanced HER2-positive and microsatellite stable colon cancer},
journal = {Precision Clinical Medicine},
year = {2025},
volume = {8},
number = {1},
doi = {10.1093/pcmedi/pbae033}
}
EUVIMED